<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154683">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01086228</url>
  </required_header>
  <id_info>
    <org_study_id>09-384</org_study_id>
    <nct_id>NCT01086228</nct_id>
  </id_info>
  <brief_title>XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan</brief_title>
  <official_title>XIENCE V/PROMUS Everolimus-Eluting Stent System Japan Post-marketing Surveillance Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this post-marketing surveillance, conducted in Japan, is to know the
      frequency, type and degree of device malfunction, to assure the safety of the medical
      device, and to collect information on evaluation of the efficacy and safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The surveillance is to be conducted in accordance with the Japanese Ministerial Ordinance
      concerning the Standards for Postmarketing Surveillance and Tests of Medical Devices.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>(This study has no primary outcome measure. All observations are of equal weight) Stent thrombosis as per ARC definition.</measure>
    <time_frame>1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Information on and the frequency of adverse events caused by antiplatelet therapy</measure>
    <time_frame>1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite rate of cardiac death and any MI (Q wave or Non-Q wave)</measure>
    <time_frame>240 days and at 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite rate of any death, any MI (QMI or NQMI), and any coronary repeat revascularization (clinically indicated [CI] vs. non-clinically indicated [non-CI])</measure>
    <time_frame>240 days and at 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite rate of any death, any MI (QMI or NQMI), and any coronary repeat revascularization (PCI or CABG, CI vs. non-CI)</measure>
    <time_frame>240 days and at 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite rate of cardiac death, any target vessel MI (QMI or NQMI), and TLR (PCI or CABG, CI vs. non-CI)</measure>
    <time_frame>240 days and at 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any death (cardiac death, vascular death, or non-cardiovascular death)</measure>
    <time_frame>240 days and at 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any MI (QMI or NQMI)</measure>
    <time_frame>240 days and at 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any repeat coronary revascularization (TLR, TVR, or non-target vessel TVR by PCI or CABG, CI vs. non-CI)</measure>
    <time_frame>240 days and at 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration and discontinuation of predefined antiplatelet therapy</measure>
    <time_frame>240 days and at 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device malfunctions</measure>
    <time_frame>240 days and at 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>240 days and at 1,2,3 (per CEC adjudication), 4 and 5 (as site reported) years post procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reference vessel diameter (RVD) and minimal lumen diameter (MLD) and % diameter stenosis (DS)</measure>
    <time_frame>pre-procedure and post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent late loss (LL) and in-stent % DS</measure>
    <time_frame>240 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-segment LL and in-segment % DS</measure>
    <time_frame>240 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>24 hours (acute) and 30 days (subacute) post procedure</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2032</enrollment>
  <condition>Angina</condition>
  <condition>Chronic Coronary Occlusion</condition>
  <condition>Stent Thrombosis</condition>
  <condition>Vascular Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>XIENCE V / PROMUS stent</arm_group_label>
    <description>Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE V / PROMUS stent</intervention_name>
    <description>Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.</description>
    <arm_group_label>XIENCE V / PROMUS stent</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Only patients in Japan, who are eligible to receive treatment for coronary arteries using
        the XIENCE V / PROMUS Everolimus-Eluting Stent System are to be enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Only XIENCE V stent(s)or PROMUS stent(s) is (are) implanted in the coronary
             vasculature during the index procedure.

        Exclusion Criteria:

          -  Neither XIENCE V stent(s) nor PROMUS stent(s) is (are) implanted in the coronary
             vasculature during the index procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Thompson</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Vascular</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104727</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 113428</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 115745</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104424</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 113645</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105015</name>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105148</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105177</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104677</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104365</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105038</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105043</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104236</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105963</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104326</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104606</name>
      <address>
        <city>Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104607</name>
      <address>
        <city>Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104528</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104536</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator#104563</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104837</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104838</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104843</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104844</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104850</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104658</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104990</name>
      <address>
        <city>Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105027</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105296</name>
      <address>
        <city>Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104864</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104898</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104906</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 114863</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104407</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 106044</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104697</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104356</name>
      <address>
        <city>Tochigi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 105092</name>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104448</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104454</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104473</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104497</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104510</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104514</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator#104481</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator # 104285</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 104294</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 17, 2015</lastchanged_date>
  <firstreceived_date>March 11, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug eluting stents</keyword>
  <keyword>Stents</keyword>
  <keyword>Angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
